hiPSCs and organoids: prediction of arrhythmogenic risks for optimized traditional Chinese medicine.
10.19540/j.cnki.cjcmm.20230706.601
- Author:
Hao-Kun SUN
1
;
Yuan GAO
2
;
Ming-Jun ZHU
3
;
Jin-Fa TANG
3
;
Ying WU
4
;
Bin LI
3
;
Rui YU
3
;
Yan WANG
1
;
Lu-Ye ZHOU
1
Author Information
1. First Clinical Medical College, Henan University of Chinese Medicine Zhengzhou 450000, China.
2. First Clinical Medical College, Henan University of Chinese Medicine Zhengzhou 450000, China Henan Engineering Research Center of Chinese Medicine Safety Evaluation and Risk Prevention and Control,the First Affiliated Hospital of Henan University of Chinese Medicine Zhengzhou 450000, China.
3. Henan Engineering Research Center of Chinese Medicine Safety Evaluation and Risk Prevention and Control,the First Affiliated Hospital of Henan University of Chinese Medicine Zhengzhou 450000, China.
4. Fuwai Central China Cardiovascular Hospital Zhengzhou 450000, China.
- Publication Type:Journal Article
- Keywords:
arrhythmia;
hiPSCs;
organoid;
traditional Chinese medicine
- MeSH:
Animals;
Humans;
Medicine, Chinese Traditional/adverse effects*;
Cardiotoxicity;
Induced Pluripotent Stem Cells;
Arrhythmias, Cardiac/chemically induced*;
Myocytes, Cardiac;
Organoids;
Drugs, Chinese Herbal/adverse effects*
- From:
China Journal of Chinese Materia Medica
2023;48(20):5404-5409
- CountryChina
- Language:Chinese
-
Abstract:
Accurate assessment of the risks associated with traditional Chinese medicine(TCM), such as the potential to induce serious cardiovascular adverse reactions including cardiac arrhythmias, is crucial. This article introduced the pharmacological evaluation strategies for cardiac safety and the progress in cardiac organ research, with a focus on discussing the application prospects of human induced pluripotent stem cells(hiPSCs) and organoids in assessing the risks of TCM-induced cardiac arrhythmias. Compared with traditional animal models, hiPSCs and organoid models provide better reference and predictive capabilities, allowing for more accurate simulation of human cardiac responses. Researchers have successfully generated various cardiac tissue models that mimic the structure and function of the heart to evaluate the effects of TCM on the heart. The hiPSCs model, by reprogramming adult cells into pluripotent stem cells and differentiating them into cardiac cells, enables the generation of personalized cardiac tissue, which better reflects individual differences and drug responses. This provides guidance for the assessment of TCM cardiac toxicity risks. By combining organoid model with cardiac safety pharmacology strategies such as electrocardiogram monitoring and ion channel function assessment, the impact of TCM on the heart can be comprehensively evaluated. In addition, the application of the Comprehensive in Vitro Proarrhythmia Assay(CiPA) approach improves the accuracy of evaluation. Applying the CiPA approach to TCM research reveals potential risks and provides a scientific basis for the clinical application and industrial development of TCM. In conclusion, organoid model and cardiac safety pharmacology evaluation strategies provide important tools for assessing the cardiac toxicity risks of TCM. The combination of hiPSCs model, comprehensive assessment methods, and the CiPA strategy enables an accurate assessment of the risks of TCM-induced cardiac arrhythmias, thus providing a scientific basis for the safe use and international recognition of TCM in clinical practice. This contributes to ensuring the safety and efficacy of TCM and promoting its clinical application and global acceptance.
